ema perspective on the regulatory approval of waskyra the first gene therapy for the treatment of wiskott aldrich syndrome

Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder. Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder.Magnific Wiskott-Aldrich syndrome is a rare inherited immune disorder affecting boys that causes eczema, immune deficiency, and bleeding. A new study shows that infusing gene-corrected stem cells provides lasting protection for patients. The FDA approved this therapy in December 2025 after citing a 93% drop in severe infections. Analysis of where the gene landed in the DNA showed blood production drawn from many different corrected cells, with no sign that the virus had disturbed cancer genes. The treatment still carries risks. Nineteen patients experienced serious adverse events. Most were infections. The study had no control group, which the authors note is inevitable in an ultra-rare disease. The FDA requires a · 15-year follow-up study to track secondary cancer risk. The path to approval is also unusual. The therapy began at an academic center, passed through pharmaceutical development and returned to Fondazione Telethon, an Italian nonprofit organization, which secured approval in Europe and the U.S. The FDA describes it as the first cell and gene therapy approved by a nonprofit applicant. A durable treatment raises the stakes for early diagnosis. In this study, symptoms started at a median age of about four months, and diagnosis followed at a median age of one year. Genetic testing of mothers in affected families, and · genome sequencing at birth, can identify boys with the disease before the first serious infection. The lesson of this study reaches beyond one rare disease.

from oncogenesis to approval the lentiviral gene therapy revolution in wiskott aldrich syndrome

Fondazione Telethon for Waskyra™, ... disorder and the first approved gene therapy developed by a nonprofit organization. Omeros for YARTEMLEA®, the first and only FDA-approved treatment for adults and children 2 years and older with hematopoietic stem cell ... Fondazione Telethon for Waskyra™, a breakthrough gene therapy for Wiskott-Aldrich syndrome (WAS) that represents the first FDA-approved gene therapy for a primary immunodeficiency disorder and the first approved gene therapy developed by a nonprofit organization. Omeros for YARTEMLEA®, the first and only FDA-approved treatment for adults and children 2 years and older with hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA), a significant and often fatal complication of stem cell transplantation. Their progress in addressing the unique challenges of these conditions is also contributing knowledge, approaches, and breakthroughs that help move science and the entire rare disease field forward." ... Mighty Therapeutics for FORZINITY™, the first therapy for Barth syndrome — a very rare, progressive, and life-limiting genetic disease affecting mitochondria — shown to improve muscle strength and quality of life. Stephen Kingsmore, MD, DSc of California, recipient of a Medical & Scientific Trailblazer Award for founding the Rady Children’s Institute for Genomic Medicine NORD Rare Disease Center of Excellence, where he pioneered whole genome sequencing, rapid genetic testing as a clinical tool, and the first comprehensive genomic carrier screening test. Mark Skinner, JD of New York, recipient of the Lifetime Achievement Award for his advocacy for bleeding disorders in New York, the U.S., and worldwide through the World Federation of Hemophilia, the National Bleeding Disorders Foundation, the HHS Advisory Committee on Blood and Tissue Safety and Availability, and NORD's Board of Directors. View original content to download multimedia:https://www.prnewswire.com/news-releases/nord-announces-the-2026-rare-impact-award-honorees-advancing-innovation-research-and-advocacy-for-rare-diseases-302889723.html · SOURCE National Organization for Rare Disorders (NORD®) ... Jazz Pharmaceuticals, Inc. Omeros Corporation ... Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder ... Get daily news updates when you subscribe to GenePool!

Recent research highlights large vessel vasculopathy as an underrecognized complication in Wiskott-Aldrich syndrome. This discovery may prompt further investigation into the cardiovascular risks associated with this rare genetic disorder.